MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 598834 | Name: Lignocaine N-oxide
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Lignocaine N-oxide is a novel metabolite of Lidocaine, an anesthetic and antiarrhythmic agent.

Chemical Structure

Lignocaine N-oxide
Lignocaine N-oxide
CAS#2903-45-9

Theoretical Analysis

MedKoo Cat#: 598834

Name: Lignocaine N-oxide

CAS#: 2903-45-9

Chemical Formula: C14H22N2O2

Exact Mass: 250.1681

Molecular Weight: 250.34

Elemental Analysis: C, 67.17; H, 8.86; N, 11.19; O, 12.78

Price and Availability

Size Price Availability Quantity
100mg USD 450.00 2 Weeks
250mg USD 950.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
Lignocaine N-oxide;
IUPAC/Chemical Name
2-((2,6-dimethylphenyl)amino)-N,N-diethyl-2-oxoethan-1-amine oxide
InChi Key
YDVXPJXUHRROBA-UHFFFAOYSA-N
InChi Code
InChI=1S/C14H22N2O2/c1-5-16(18,6-2)10-13(17)15-14-11(3)8-7-9-12(14)4/h7-9H,5-6,10H2,1-4H3,(H,15,17)
SMILES Code
CCN(CC)(CC(Nc1c(C)cccc1C)=O)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
Lignocaine N-oxide is a novel metabolite of Lidocaine, an anesthetic and antiarrhythmic agent.
In vitro activity:
The MKN45 cell viability, proliferation, and apoptosis were determined after cells were treated by lidocaine. According to CCK-8 assay, cell viability was inhibited after cells were cultured with different concentrations of lidocaine (1, 5 and 10 mM) (Fig. 1a). Lidocaine inhibited migration (p < 0.05, Fig. 2a) and down-regulated MMP-2, and -9 expression (p < 0.05, Fig. 2b). Reference: BMC Cancer. 2019 Mar 15;19(1):233. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6419442/
In vivo activity:
In this study, the potential role of lidocaine in DPN is explored, and the possible mechanisms are investigated. The rat DPN model is constructed through administration of streptozotocin (STZ, 60 mg/kg). The experimental results demonstrate that lidocaine remarkably downregulates the mRNA and protein expressions of the c-Jun signaling pathway in serum and DRGs induced with DPN. Reference: Contrast Media Mol Imaging. 2022 Aug 17;2022:1888153. https://pubmed.ncbi.nlm.nih.gov/36072636/

Preparing Stock Solutions

The following data is based on the product molecular weight 250.34 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Liu X, Zheng F, Tian L, Li T, Zhang Z, Ren Z, Chen X, Chen W, Li K, Sheng J. Lidocaine inhibits influenza a virus replication by up-regulating IFNα4 via TBK1-IRF7 and JNK-AP1 signaling pathways. Int Immunopharmacol. 2023 Jan 11;115:109706. doi: 10.1016/j.intimp.2023.109706. Epub ahead of print. PMID: 36638664. 2. Sui H, Lou A, Li Z, Yang J. Lidocaine inhibits growth, migration and invasion of gastric carcinoma cells by up-regulation of miR-145. BMC Cancer. 2019 Mar 15;19(1):233. doi: 10.1186/s12885-019-5431-9. PMID: 30876463; PMCID: PMC6419442. 3. Luo J, Wu D, Wu Q, Chen Y, Gan Y, He M, Sun W, Ai Y, Su Q, Zou X, Wang D. Lidocaine Ameliorates Diabetic Peripheral Neuropathy in Streptozotocin-Induced Diabetic Rats through Modulating the c-Jun Signaling Pathway. Contrast Media Mol Imaging. 2022 Aug 17;2022:1888153. doi: 10.1155/2022/1888153. PMID: 36072636; PMCID: PMC9402326. 4. Chen YC, Chang HN, Pang JS, Lin LP, Chen JM, Yu TY, Tsai WC. Lidocaine Inhibited Tendon Cell Proliferation and Extracellular Matrix Production by Down Regulation of Cyclin A, CDK2, Type I and Type III Collagen Expression. Int J Mol Sci. 2022 Aug 7;23(15):8787. doi: 10.3390/ijms23158787. PMID: 35955918; PMCID: PMC9368801.
In vitro protocol:
1. Liu X, Zheng F, Tian L, Li T, Zhang Z, Ren Z, Chen X, Chen W, Li K, Sheng J. Lidocaine inhibits influenza a virus replication by up-regulating IFNα4 via TBK1-IRF7 and JNK-AP1 signaling pathways. Int Immunopharmacol. 2023 Jan 11;115:109706. doi: 10.1016/j.intimp.2023.109706. Epub ahead of print. PMID: 36638664. 2. Sui H, Lou A, Li Z, Yang J. Lidocaine inhibits growth, migration and invasion of gastric carcinoma cells by up-regulation of miR-145. BMC Cancer. 2019 Mar 15;19(1):233. doi: 10.1186/s12885-019-5431-9. PMID: 30876463; PMCID: PMC6419442.
In vivo protocol:
1. Luo J, Wu D, Wu Q, Chen Y, Gan Y, He M, Sun W, Ai Y, Su Q, Zou X, Wang D. Lidocaine Ameliorates Diabetic Peripheral Neuropathy in Streptozotocin-Induced Diabetic Rats through Modulating the c-Jun Signaling Pathway. Contrast Media Mol Imaging. 2022 Aug 17;2022:1888153. doi: 10.1155/2022/1888153. PMID: 36072636; PMCID: PMC9402326. 2. Chen YC, Chang HN, Pang JS, Lin LP, Chen JM, Yu TY, Tsai WC. Lidocaine Inhibited Tendon Cell Proliferation and Extracellular Matrix Production by Down Regulation of Cyclin A, CDK2, Type I and Type III Collagen Expression. Int J Mol Sci. 2022 Aug 7;23(15):8787. doi: 10.3390/ijms23158787. PMID: 35955918; PMCID: PMC9368801.
1: Patterson LH, Hall G, Nijjar BS, Khatra PK, Cowan DA. In-vitro metabolism of lignocaine to its N-oxide. J Pharm Pharmacol. 1986 Apr;38(4):326. PubMed PMID: 2872305.